CA2012257A1 - Anti-snoring formulations - Google Patents
Anti-snoring formulationsInfo
- Publication number
- CA2012257A1 CA2012257A1 CA 2012257 CA2012257A CA2012257A1 CA 2012257 A1 CA2012257 A1 CA 2012257A1 CA 2012257 CA2012257 CA 2012257 CA 2012257 A CA2012257 A CA 2012257A CA 2012257 A1 CA2012257 A1 CA 2012257A1
- Authority
- CA
- Canada
- Prior art keywords
- yohimbine
- formulation
- person
- snores
- hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010041235 Snoring Diseases 0.000 title claims abstract description 13
- 238000009472 formulation Methods 0.000 title claims abstract description 12
- 239000000203 mixture Substances 0.000 title claims abstract description 12
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 claims abstract description 11
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960000317 yohimbine Drugs 0.000 claims abstract description 11
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 claims abstract description 11
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 claims abstract description 11
- 230000007958 sleep Effects 0.000 claims abstract description 6
- 150000002148 esters Chemical class 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- -1 carboxylic acid methyl ester Chemical class 0.000 claims abstract description 3
- 239000003937 drug carrier Substances 0.000 claims abstract description 3
- PIPZGJSEDRMUAW-VJDCAHTMSA-N hydron;methyl (1s,15r,18s,19r,20s)-18-hydroxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate;chloride Chemical compound Cl.C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 PIPZGJSEDRMUAW-VJDCAHTMSA-N 0.000 claims description 12
- 229960000949 yohimbine hydrochloride Drugs 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 4
- 239000007891 compressed tablet Substances 0.000 claims description 2
- 229940090523 yocon Drugs 0.000 description 4
- 201000001881 impotence Diseases 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000000674 adrenergic antagonist Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000001856 erectile effect Effects 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
ABSTRACT
A formulation for use to treat a person who snores when he or she sleeps, the said formulation comprising an effective amount of yohimbine (3 ?-15 ? -20.beta.-17? -hydroxy yohimbine-16?carboxylic acid methyl ester) and pharmaceutically tolerable forms thereof (for example, salts, esters and the like), in a pharmaceutically acceptable carrier.
A formulation for use to treat a person who snores when he or she sleeps, the said formulation comprising an effective amount of yohimbine (3 ?-15 ? -20.beta.-17? -hydroxy yohimbine-16?carboxylic acid methyl ester) and pharmaceutically tolerable forms thereof (for example, salts, esters and the like), in a pharmaceutically acceptable carrier.
Description
201~257 FIELD OF INVENTION
This invention relates to formulations suitable for treating snoring.
BACKGROUND OF THE INVENTION
Snoring is a very serious problem, not only for the individuals but also with the partner wlth whom such lndividual sleeps.
It is therefor an object of this invention to provide formulations suitable for use to treat persons who snore when they sleep and a method of treating such a person who snores when sleeping.
Further and other objects of the invention will be realized by those skilled in the art from the following summary of the invention and detailed description thereof.
SUMMARY OF THE INVENTION
According to one aspect of the invention a formulation is provided.for use to treat a person who snores when he or she sleeps, the said formulatlon comprising an effective amount of yohimbine (3c7~-15C~-20~-17G~-hydroxy yohimbine-16~C~carboxylic acid methyl ester) and pharmaceutically tolerable forms thereof (for example, salts, esters, and the like), in a pharmaceutically acceptable carrier. One formulation may comprise a compressed tablet which contains (1/12 gr.) 5.4 mg of yohimbine hydrochloride in a pharmaceutically tolerable carrier.
This formulation may be taken by the person suffering from snoring before bedtime.
According to another aspect of the invention an improved treatment for a person who snores may co~prise the administration to the patient, an effective amount of the yohimbine or any pharmaceutically tolerable thereof (for example, salts thereof [e.g. hydrochloride], esters, form and the like) in a pharmaceutically tolerable carrier for the treatment of snoring. Such process may, for example, comprise the administration of one tablet of (1/12 grain) 5.~ mg of yohimbine hydrochloride before bedtime.
One source of the yohimbine is found in a preparation Yocon (T.M.) manufactured by Palisades Pharmaceuticals Inc., Tenafly, New Jersey U.S.A 07670. A
distributor of the Yocon (T.M.) is Glenwood Laboratories Canada Limited, Mississauga, Ontario, L5T lH3.
Yohimbine is described in the literature [the Product monograph and "Effect of Yohimbine Hydrochloride On Erectile Impotence: A Double-Blind Study" The Journal of Uroloay Vol.
141, June] as an alpha adrenergic blocking agent having contraindications of renal or herpatic insufficiency. The user of the drug, according to the product monograph provided by the manufacturers of Yocon (T.M.) is warned under precautions that "Yohimbine may injure kidneys and cause hypotension. The possibility of a fatal overdose of yohimbine when associated with ingestion of alcohol must be considered. An overdose treatment is provided as follows:
"Conduct the gastric lavage and adMinister activated charcoal (four tablespoons: 500 ml of water). Treat excitation or convulsions with the barbituate".
For use as an alpha adrenergic blocking agent Yocon (T.M.) is to be administered to an adult one tablet up to 3 times daily or as directed by a physician. The tablets are white uncoated spherical tablets containing yohimbine hydrochloride 5.4 mg (1/12 grain), bottled in 100 or 1000.
The article entitled "Effect of Yohimbine _ 3 _ 20~Z~7 Hydrochloride on Erectile Impotence: A Double-Blind Study"
provides in the abstract that the 39% response by patients taking yohimbine hydrochloride on erectile dysfunction was encouraging.
By way of tests, Applicant has administered such a tablet (described above) of 1/12 grain (5.4 mg) of yohimbine hydrochloride to patients who snored when they slept prior to bedtime (e.g. one half hour). The partners of the patients did not detect any snoring through the night.
As many changes can be made to the invention without departing from the scope of the invention, it is intended that all material contained herein be interpreted as illustrative of the invention and not in a limiting sense.
This invention relates to formulations suitable for treating snoring.
BACKGROUND OF THE INVENTION
Snoring is a very serious problem, not only for the individuals but also with the partner wlth whom such lndividual sleeps.
It is therefor an object of this invention to provide formulations suitable for use to treat persons who snore when they sleep and a method of treating such a person who snores when sleeping.
Further and other objects of the invention will be realized by those skilled in the art from the following summary of the invention and detailed description thereof.
SUMMARY OF THE INVENTION
According to one aspect of the invention a formulation is provided.for use to treat a person who snores when he or she sleeps, the said formulatlon comprising an effective amount of yohimbine (3c7~-15C~-20~-17G~-hydroxy yohimbine-16~C~carboxylic acid methyl ester) and pharmaceutically tolerable forms thereof (for example, salts, esters, and the like), in a pharmaceutically acceptable carrier. One formulation may comprise a compressed tablet which contains (1/12 gr.) 5.4 mg of yohimbine hydrochloride in a pharmaceutically tolerable carrier.
This formulation may be taken by the person suffering from snoring before bedtime.
According to another aspect of the invention an improved treatment for a person who snores may co~prise the administration to the patient, an effective amount of the yohimbine or any pharmaceutically tolerable thereof (for example, salts thereof [e.g. hydrochloride], esters, form and the like) in a pharmaceutically tolerable carrier for the treatment of snoring. Such process may, for example, comprise the administration of one tablet of (1/12 grain) 5.~ mg of yohimbine hydrochloride before bedtime.
One source of the yohimbine is found in a preparation Yocon (T.M.) manufactured by Palisades Pharmaceuticals Inc., Tenafly, New Jersey U.S.A 07670. A
distributor of the Yocon (T.M.) is Glenwood Laboratories Canada Limited, Mississauga, Ontario, L5T lH3.
Yohimbine is described in the literature [the Product monograph and "Effect of Yohimbine Hydrochloride On Erectile Impotence: A Double-Blind Study" The Journal of Uroloay Vol.
141, June] as an alpha adrenergic blocking agent having contraindications of renal or herpatic insufficiency. The user of the drug, according to the product monograph provided by the manufacturers of Yocon (T.M.) is warned under precautions that "Yohimbine may injure kidneys and cause hypotension. The possibility of a fatal overdose of yohimbine when associated with ingestion of alcohol must be considered. An overdose treatment is provided as follows:
"Conduct the gastric lavage and adMinister activated charcoal (four tablespoons: 500 ml of water). Treat excitation or convulsions with the barbituate".
For use as an alpha adrenergic blocking agent Yocon (T.M.) is to be administered to an adult one tablet up to 3 times daily or as directed by a physician. The tablets are white uncoated spherical tablets containing yohimbine hydrochloride 5.4 mg (1/12 grain), bottled in 100 or 1000.
The article entitled "Effect of Yohimbine _ 3 _ 20~Z~7 Hydrochloride on Erectile Impotence: A Double-Blind Study"
provides in the abstract that the 39% response by patients taking yohimbine hydrochloride on erectile dysfunction was encouraging.
By way of tests, Applicant has administered such a tablet (described above) of 1/12 grain (5.4 mg) of yohimbine hydrochloride to patients who snored when they slept prior to bedtime (e.g. one half hour). The partners of the patients did not detect any snoring through the night.
As many changes can be made to the invention without departing from the scope of the invention, it is intended that all material contained herein be interpreted as illustrative of the invention and not in a limiting sense.
Claims (4)
1. A formulation for use to treat a person who snores when he or she sleeps, the said formulation comprising an effective amount of yohimbine (3 ?-15 ?-20.beta.-17?-hydroxy yohimbine-16 ?carboxylic acid methyl ester) and pharmaceutically tolerable forms thereof (for example, salts, esters and the like), in a pharmaceutically acceptable carrier.
2. The formulation of Claim 1, wherein the formulation comprises a compressed tablet which contains (1/12 of a gr.) 5.4 mg of yohimbine hydrochloride.
3. An improved treatment for a person who snores, the process comprises the administration prior to sleep to the patient of an effective amount of yohimbine or any pharmaceutically tolerable form thereof (for example, salts, esters and the like) in a pharmaceutically tolerable carrier.
4. The process of Claim 1, wherein the yohimbine may comprise a tablet of (1/12 grain) 5.4 mg of yohimbine hydrochloride.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2012257 CA2012257A1 (en) | 1990-03-15 | 1990-03-15 | Anti-snoring formulations |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2012257 CA2012257A1 (en) | 1990-03-15 | 1990-03-15 | Anti-snoring formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2012257A1 true CA2012257A1 (en) | 1991-09-15 |
Family
ID=4144529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2012257 Abandoned CA2012257A1 (en) | 1990-03-15 | 1990-03-15 | Anti-snoring formulations |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2012257A1 (en) |
-
1990
- 1990-03-15 CA CA 2012257 patent/CA2012257A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5096715A (en) | Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist | |
| TW416854B (en) | Buccal delivery of glucagon-like insulinotropic peptides | |
| FI945621A0 (en) | Regulated release formulation | |
| DE69521688T2 (en) | PHARMACEUTICAL Brewing Preparations Containing Biodegradable Microcapsules For Controlled Release Of Active Ingredients | |
| IE872110L (en) | Oral therapeutic system having systemic action | |
| US5082665A (en) | Anti-snoring formulations using yohimbine | |
| CA2601289A1 (en) | Once-a-day oxycodone formulations | |
| CZ176495A3 (en) | The use of riluzol for preparing a medicament suitable for treating parkinson's disease and parkinson's syndromes | |
| YU2494A (en) | PHARMACEUTICAL FORMULATION FOR TREATMENT OF NICOTINE SUBSTANCE | |
| UA27848C2 (en) | ORAL PHARMACEUTICAL FORM FOR THE TREATMENT OF CENTRAL STATES OF DOPAMIN DEFICIENCY | |
| JP3018160B2 (en) | Drug for reducing dysmenorrhea and / or premenstrual syndrome | |
| RU95101385A (en) | Products containing g-csf and tnf-binding protein | |
| DE69922017D1 (en) | MEDICINAL PRODUCT AND METHOD FOR TREATING INTRACELLULAR INFECTIONS | |
| GB2074863A (en) | Therapeutic compositions of physostigmine compounds | |
| JPH0436243A (en) | Hypnotic sedative | |
| CA2012257A1 (en) | Anti-snoring formulations | |
| AR002727A1 (en) | THE USE OF RIDOGREL FOR THE MANUFACTURE OF A MEDICATION USEFUL FOR THE TREATMENT OF DIGESTIVE INFLAMMATORY DISEASES, A PHARMACEUTICAL COMPOSITION INCLUDING RIDOGREL AND A PROCEDURE FOR PREPARING SUCH COMPOSITION. | |
| KR100208969B1 (en) | Anti-ulcers drug containing extract from chap-rice | |
| Viukari et al. | Diazepam, promethazine and propiomazine as hypnotics in elderly inpatients | |
| MX9800809A (en) | Process for preparing solid dosage forms of very low-dose drugs. | |
| Holt et al. | Intranasal β-agonist in allergic rhinitis. | |
| Bendtsen et al. | Duodenal ulcer healing on 2 g of sucralfate daily at bedtime compared to 1 g four times daily | |
| MORTENSEN et al. | daily zyxwvutsrqponmlkj | |
| JPS6360926A (en) | Cold remedy | |
| CA2187153A1 (en) | Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |